RxDoctor Payments Data

Abigail Vecellio, PA

Physician Assistant · Fountain Hill, PANPI 1306503362

Payments from drug & device makers

$2,904in general payments, 2019–2025

Across 60 payments — averaging $48.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$829
  • Gilead$483
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$449
  • Regeneron Healthcare Solutions, Inc.$313
  • AbbVie$288
  • E.r. Squibb & Sons, L.L.C.$150
  • plus $392 from 5 others

What the payments were for

  • Travel & lodging$51418%
  • Food & beverage$2,29079%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,904 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$53,183
Medicare patients
515
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide49$39,874
XifaxanRifaximin11$23,471
Sucralfate44$10,952
Dexlansoprazole DrDexlansoprazole19$6,030
Famotidine189$4,745
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates68$4,655
Omeprazole408$3,982
Pantoprazole Sodium343$3,654
Esomeprazole Magnesium62$3,167
CholestyramineCholestyramine (With Sugar)33$1,880
Colestipol Hcl27$1,668
Dicyclomine Hcl100$1,283
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl70$1,071
Rabeprazole Sodium16$1,010
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine27$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$288$39,87449 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$449$23,47111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Fountain Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →